BioNTech Wields Its Broadest ASCO Arsenal Yet, but Analysts Remain Sharply Divided on the Path to Approval

BioNTech descended on Chicago’s ASCO conference with the deepest clinical package in its history — more than 25 studies, 13 of them pivotal — yet the stock continues to trade nearly a fifth below its 52-week high. The disconnect reflects a fundamental disagreement on the sell side: some see a pipeline approaching critical mass, while others warn that the oncology transition remains a high-risk bet.

The centrepiece of the presentation was Pumitamig (BNT327), a bispecific immunomodulator combining checkpoint inhibition with VEGF-A neutralisation. Data from the Phase?2 portion of the global ROSETTA Lung?02 trial, cut off as of 13?April?2026 with a median follow?up of 9.0?months, showed confirmed objective response rates of 57.1?% in non?squamous and 68.4?% in squamous non?small?cell lung cancer. The disease?control rate reached 100?% across both histologies. Notably, the lower tested dose delivered even higher responses: 63.6?% and 72.7?%, respectively. Broken down by PD?L1 expression, the overall response rate ranged from 47.6?% in TPS?<?1?% to 77.8?% in TPS 1?49?% and 100?% in TPS???50?%.

Safety remains a close watch for the market. Treatment?related adverse events of Grade?3 or higher occurred in 48.8?% of patients, with 23.3?% attributed specifically to Pumitamig. Four patients (9.3?%) discontinued treatment, while immune?related side effects were seen in 16 patients, two of which were Grade?3 or worse. Nine bleeding events were reported, including one Grade?3 case.

This marks the third consistent global dataset for Pumitamig in combination with chemotherapy, following earlier signals in small?cell lung cancer and triple?negative breast cancer. The development programme is accelerating: seven global Phase?3 trials with registration potential are now active across tumour types including those three plus colorectal and gastric cancers. BioNTech and partner Bristol?Myers?Squibb have already started the randomised Phase?3 portion of ROSETTA Lung?02, pitting Pumitamig plus chemo against pembrolizumab plus chemo, with blinded independent central review of progression?free survival as the primary endpoint. Two further NSCLC Phase?3 studies — ROSETTA Lung?201 (post?chemoradiation in Stage?III) and ROSETTA Lung?202 (first?line in PD?L1???50?%) — are also underway.

Should investors sell immediately? Or is it worth buying BioNTech?

Beyond Pumitamig, BioNTech debuted three antibody?drug conjugates on a single conference stage for the first time. The lead candidate, trastuzumab pamirtecan, a HER2?directed ADC, posted a confirmed overall response rate of 47.9?% and a median progression?free survival of 8.1?months in a Phase?2 cohort of 145 patients with HER2?positive advanced endometrial cancer. Already carrying FDA Fast Track and Breakthrough Therapy designations, the molecule is on track for a Biologics License Application submission in 2026, subject to regulatory feedback, while a Phase?3 study versus chemotherapy is being initiated. Two other ADCs — the HER3?targeted BNT326/YL202 and the B7H3?directed BNT324/DB?1311 — are being evaluated in metastatic castration?resistant prostate cancer.

The breadth of the pipeline has not, however, bridged the analyst divide. UBS upgraded the stock to Buy in late May with a $135 price target, while Canaccord Genuity and Wells Fargo reaffirmed their Buy ratings. On the other side, Bernstein initiated coverage at Market Perform and a $96 target, citing the historically high failure rate of checkpoint inhibitors in demonstrating statistically significant survival benefits. J.P.?Morgan holds at Hold with a $100 target. The consensus from 17 analysts stands at $125.45 — well above the current level.

BioNTech’s financial runway remains deep. As of 31?March?2026, the company held €16.76?billion in cash, equivalents and securities. First?quarter revenue fell to €118.1?million from €182.8?million a year earlier, driven by lower COVID?19 vaccine sales, while R&D spending rose to €557.0?million from €525.6?million, fuelled by oncology and ADC programmes. The net loss widened to €531.9?million from €415.8?million. Management’s full?year 2026 revenue guidance stands at $2.3?2.6?billion, and a $1?billion share buyback programme is already running.

BioNTech at a turning point? This analysis reveals what investors need to know now.

The stock closed Friday at €82.35, up 2.68?% on the day but still roughly 19?% below the 52?week high of €101.90 and 14?% above the March low of €72.50. With 15 active Phase?3 studies targeted by year?end and seven late?stage data packages still due in 2026 — including the planned BLA filing for trastuzumab pamirtecan — the next few months will test whether the ASCO data dump can convert sceptical investors into believers. The pivotal Phase?3 readouts for Pumitamig, expected later this year, will be the next crucial inflection point.

Ad

BioNTech Stock: New Analysis - 31 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH | boerse | 69452392 |